Home / Pharmaceuticals / Chronic Myeloid Leukemia (CML) Treatment Market By Type (Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy and Stem Cell Transplant), - Growth, Share, Opportunities & Competitive Analysis, 2016 -2023

Chronic Myeloid Leukemia (CML) Treatment Market By Type (Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy and Stem Cell Transplant), - Growth, Share, Opportunities & Competitive Analysis, 2016 -2023

Published: Sep 2016 | Report Code: 58082-09-16

The report titled “Chronic Myeloid Leukemia (CML) Treatment Market- Growth, Future Prospects, and Competitive Analysis, 2016 – 2023” offers strategic insights into the overall chronic myeloid leukemia (CML) treatment market along with the market size and estimates for the duration 2013 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of drugs, and different geographies. According to the Leukemia CARE, Chronic myeloid leukaemia (CML) is a form of blood cancer, which affects the white blood cells known as myeloid cells. It is a slowly progressing form of leukaemia. In CML the bone marrow carries out overproduction of white cells or granulocytes which steadily crowd the bone marrow and ultimately interfering with normal blood cell production. There are no specific signs or symptoms which would allow a diagnosis of CML to be made. The most common signs and symptoms are caused by the bone marrow being unable to produce enough normal blood cells. CML accounts for 15% of all leukemias in adults and approximately 8,220 new cases of CML will be diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 populations.

The market experts suggest that, CML is not considered curable with standard treatments; with the possible exception of stem cell transplants in a small number of younger and/or fitter patients. A new class of drugs called tyrosine kinases (TKIs) or BCR-ABL inhibitors has transformed treatment of CML. Currently existing BCR-ABL inhibitors form the stronghold of CML treatment comprises first-generation imatinib and more effective second-generation BCR-ABL inhibitors nilotinib and dasatinib, with ponatinib and bosutinib having been recently approved for market inclusion. A few published reports exhibit that nilotinib and dasatinib have high efficacy than imatinib in first-line chronic-phase CML (CML-CP), allowing more patients to get effective results, comparatively more rapid responses related with enhanced results.

The geographical segmentation comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. Market size and forecast for these segments during 2013 to 2023 and their CAGRs for the period 2016 to 2023 are provided in this report.

The chronic myeloid leukaemia (CML) market is observed as the most diversified and competitive market comprising large number of players.  The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, Otsuka Pharmaceutical Co., Ltd. and others.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Treatment Type, 2013-2023 (Value %)
2.2 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Geography, 2015 (Value %)

Chapter 3 Global ChroniC Myeloid Leukemia (CML) Treatment Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence and awareness of leukemia is boosting the need for research and development
3.2.2 Incessant developments in stem cell therapy is expected to provide an effective options against drugs
3.3 Market Restraints
3.3.1 Dry drug development pipeline of CML is expected to slow down the treatment of CML
3.4 Market Opportunities
3.4.1 Future in non-invasive and efficient treatment options
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Chronic Myeloid Leukemia (CML) Treatment, by Key Players

Chapter 4 Global Chronic Myeloid Leukemia (CML) Treatment Market Analysis, By Treatment Type
4.1 Overview
4.2 Targeted Therapy
4.2.1 Imatinib
4.2.2 Dasatinib
4.2.3 Nilotinib
4.2.4 Bosutinib
4.2.5 Ponatinib
4.3 Chemotherapy
4.4 Radiation Therapy
4.5 Splenectomy
4.6 Stem Cell Transplant

Chapter 5 Global Chronic Myeloid Leukemia (CML) Treatment Market, By Geography
5.1 Preface
5.2 North America
5.3 Europe
5.4 Asia Pacific
5.5 Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Novartis AG
6.1.1 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.3 Teva Pharmaceuticals Industries Ltd.
6.3.1 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.4 ARIAD Pharmaceuticals, Inc.
6.4.1 ARIAD Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.5 Pfizer, Inc.
6.5.1 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.6 Hospira, Inc.
6.6.1 Hospira, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.7 Prism Pharmaceuticals
6.7.1 Prism Pharmaceuticals: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.8 Incyte Corporation
6.8.1 Incyte Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.9 Bio-Path Holdings
6.9.1 Bio-Path Holdings: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.10 Stragen Pharma SA
6.10.1 Stragen Pharma SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.11 Otsuka Pharmaceutical Co., Ltd.
6.11.1 Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List of Figures

FIG. 1 Chronic Myeloid Leukemia (CML) Treatment Market: Research Methodology
FIG. 2 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Treatment Type, 2013-2023 (Value %)
FIG. 3 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Geography, 2015 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2015
FIG. 5 Imatinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 6 Dasatinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 7 Nilotinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 8 Bosutinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 9 Ponatinib Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 10 Chemotherapy Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 11 Radiation Therapy Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 12 Splenectomy Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 13 Stem Cell Transplant Market in CML Treatment, 2013 – 2023 (USD Mn)
FIG. 14 North America Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)
FIG. 15 Europe Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)
FIG. 16 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)
FIG. 17 Latin America Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)
FIG. 18 Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Market , 2013 – 2023 (USD Mn)

List of Tables

TABLE 1 Market Competition Assessment: Chronic Myeloid Leukemia (CML) Treatment, by Key Players
TABLE 2 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Treatment Type, 2013-2023 (USD Mn)
TABLE 3 Global Targeted Therapy Market for CML Treatment, by Drugs, 2013-2023 (USD Mn)
TABLE 4 Global Chronic Myeloid Leukemia (CML) Treatment Market, by Geography, 2013 – 2023 (USD Mn)
TABLE 5 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 6 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 ARIAD Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Hospira, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 11 Prism Pharmaceuticals: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 12 Incyte Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 Bio-Path Holdings: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Stragen Pharma SA: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

 

Based on the type of treatment, the global chronic myeloid leukemia (CML) treatment market is segmented as follows:

  • Targeted Therapy
    • Imatinib
    • Dasatinib
    • Nilotinib
    • Bosutinib
    • Ponatinib
  • Chemotherapy
  • Radiation Therapy
  • Splenectomy
  • Stem Cell Transplant

According to American Cancer Society, chronic myeloid leukemia (CML) cells contain an oncogene, BCR-ABL, that isn't found in normal cells. These genes possess an ability to make a protein, BCR-ABL, which causes CML cells to grow and reproduce at abnormally quick rate. BCR-ABL is a type of protein known as a tyrosine kinase. Drugs known as tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the standard treatment for CML. Medical practitioners suggest that, the BCR-ABL protein inhibits cell apoptosis and DNA repair, leading to genomic instability and further genetic abnormalities. Oncologists also suggest that, earlier stem cell therapy was commonly used to treat CML before the launch of modern targeted therapy drugs like imatinib. The drugs that were available earlier did not work very well, and less than half of patients survived more than 5 years after diagnosis. Now, targeted drugs like imatinib are the standard treatment, and transplants are being used less often.  In 2015, targeted therapy accounted for the largest share of CML treatment market due to high efficiency, increased life expectancy, insurance cover in developed and developing countries, and rising patient’s awareness related to the targeted therapy. A stem cell transplant may be an option for some younger patients, or patients who are intolerant or resistant to TKIs - providing them with a better chance of cure.

Chronic Myeloid Leukemia (CML) Treatment Market
  

For the purpose of this study, the global chronic myeloid leukemia (CML) market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Chronic Myeloid Leukemia (CML) Treatment Market

In base year 2015, North America was observed as the leading geographical region in chronic myeloid leukemia treatment market due to rising diagnosis rate of chronic myeloid leukemia, market entry of novel targeted drug therapies and organized medical insurance environment. The American Cancer Society's estimates that in year 2016, about 8,220 new cases will be diagnosed with CML (4,610 in men and 3,610 in women), and about 1,070 people will die of CML (570 men and 500 women). According to research study published in Blood Journal stated that, the constant research carried out on chronic myelogenous leukemia (CML) treatment resulted into USFDA approval of 3 drugs in 2012 for the treatment of CML: bosutinib, ponatinib, and omacetaxine. This is in addition to 3 others approved in the last decade: imatinib, dasatinib, and nilotinib. In 2013, it was observed that 3 new drugs approved have been priced at high levels: ponatinib at US$ 138,000 per year, omacetaxine at US$ 28,000 for induction and US$ 14,000 per maintenance course, and bosutinib at ∼US$ 118,000 per year. Cancer drug prices vary widely in different geographic regions. This supports the fact that drug prices reflect geopolitical and socioeconomics dynamics of the region unrelated to the cost of drug development. In the United States, prices represent the extreme end of high prices, a reflection of a “free market economy” and the notion that “one cannot put a price on a human life,” as well as a failure of government and insurers to more actively negotiate pricing for anticancer and other pharmaceuticals, in contrast to practices in other parts of the world. Overall CML treatment market is growing slowly but upcoming drug approvals are expected to boost the market.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients